Farhad Hafezi

Categories: | | | | |
ELZA at ESCRS 2019: a record 21 presentations
The annual meeting of the European Society of Cataract and Refractive Surgeons (ESCRS) was held in Paris between 14–18 September 2019, and ELZA’s surgeons and researchers presented a record 21 presentations during the congress – so what did ELZA at ESCRS manage to achieve? Our team presented at 8 free paper presentations and a further 8 instructional courses, as well as three moderated poster sessions, two e-posters (as well as instructing in 1 wet lab too).

READ

Categories: | |
MEACO: ELZA goes to Jordan
I was honoured to be invited to give a series of talks during this year’s MEACO congress, held in the Hilton Dead Sea & Spa Hotel in Amman, Jordan, where I reviewed the latest thinking in cross-linking and presented the latest clinical and laboratory research work from our research group and our collaborators.

READ

Categories: |
Podium Power: Farhad Hafezi in Zagreb
ELZA’s medical director, Prof. Dr. Farhad Hafezi was invited to be the guest lecturer at the Croatian Ophthalmology and Optometric Society’s Contact Lens course, where he presented the latest corneal cross-linking (CXL) research and reviewed current best clinical practice for the treatment of keratoconus and iatrogenic ectasia.

READ

Categories: |
Understanding your eye’s strengths and weaknesses

READ

Categories: |
Can Cross-Linking (CXL) treat Terrien’s Marginal Degeneration (TMD)?
Terrien’s Marginal Degeneration (TMD) is a progressive thinning of the cornea at its edges, next to the sclera (the white part of the eye). Can corneal cross-linking (CXL) treat TMD like it can treat other corneal thinning disorders like keratoconus? To find out, click on the link to read more!

READ

Categories: |
Why I’m a Frequent Flyer
I fly. A lot. To educate, to inform, to train scientists and surgeons in the latest advances in cross-linking. Yes, I worry about my carbon footprint. Yes, I miss my family when I’m gone. But it’s important that it’s done, and I explain in this blog post exactly why that’s true.

READ

Categories: |
Why do we offer observerships at ELZA?
ELZA takes observerships seriously. When we offer somebody an observership placement, we’ll plan that person’s time carefully to give them the maximum exposure to the clinical, scientific and administrative aspects of the clinic.

READ

Categories: | | | |
ELZA’s Surgeons on the Podium and in the News
For the second year in a row, Dion Paridaens gave a series of lectures at the 2019 ESASO Course on Orbital, Lacrimal & Oculoplastic Surgery Course in Lugano, Switzerland (21–25 January, 2019).

READ

Categories: |
Cross-Linking in the USA – Part 3: Off-Label applications
Epi-on CXL aims to sidestep epi-off CXL’s issues by leaving the epithelium intact, however, this comes at a price of reduced efficacy – no clinical trial published to date has convincingly shown epi-on CXL to be as effective as epi-off CXL at the most important outcome: stopping keratoconus from progressing.

READ

Categories: |
Cross-Linking in the USA – Part 4: The Future
What is the future of corneal cross-linking (CXL)? PACK-CXL to treat corneal infections without antibiotics, refractive cross-linking and better Kpros…

READ

Load More
.
.